China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III immunogenic bridge study for its COVID-19 variant mRNA vaccine candidate, RQ3033, co-developed with Fudan University and RNACure. The vaccine is specifically targeting the Omicron XBB.1.5 variant and has demonstrated good efficacy and safety in the trial.
The study indicated that RQ3033 elicits a robust immune response. In individuals aged 18 and above who had completed the primary COVID-19 vaccination series, the geometric mean titer (GMT) of RQ3033 against the SARS-CoV-2 Omicron EG.5 mutant 14 days after the booster immunization was 946.01, significantly higher than the control group’s GMT of 287.20, thus meeting the statistical superiority evaluation standard.
In terms of safety, the vaccine showed an overall good safety profile following the booster immunization in the same demographic. The adverse reactions were primarily of grade 1 and grade 2, with the incidence of grade 3 adverse reactions being 3.67% in the test group and 3.77% in the control group. No serious adverse events (SAEs) related to the vaccination were reported. The incidence of adverse reactions for RQ3033 was generally on par with that of similar COVID-19 mRNA vaccines available internationally.
These positive results position RQ3033 as a promising candidate in the ongoing fight against COVID-19, particularly in providing protection against the Omicron XBB.1.5 variant.- Flcube.com
